Endoscopic duodenal-jejunal bypass liner rapidly improves plasma parameters of nonalcoholic fatty liver disease
| Autor: | Jan Greve, Mandy F. Joosten, Nicole D. Bouvy, Ger H. Koek, Sander S. Rensen, Wim A. Buurman, Charlotte de Jonge |
|---|---|
| Přispěvatelé: | Surgery, Interne Geneeskunde, RS: NUTRIM - R2 - Gut-liver homeostasis, RS: NUTRIM - R1 - Metabolic Syndrome |
| Jazyk: | angličtina |
| Rok vydání: | 2013 |
| Předmět: |
Adult
Male BIOMARKER medicine.medical_specialty Steatosis Adolescent WEIGHT-LOSS Type 2 diabetes Gastroenterology digestive system Duodenal-jejunal bypass liner STEATOHEPATITIS Plasma Young Adult Insulin resistance Liver Function Tests Weight loss Non-alcoholic Fatty Liver Disease Internal medicine Nonalcoholic fatty liver disease medicine Humans Gamma-glutamyltransferase Aged BARIATRIC SURGERY Hepatology biology business.industry Anastomosis Surgical Stomach Albumin NONINVASIVE DIAGNOSIS Middle Aged medicine.disease digestive system diseases Intestine APOPTOSIS Fatty Liver Endocrinology Treatment Outcome biology.protein Female Steatohepatitis medicine.symptom Insulin Resistance business |
| Zdroj: | Clinical gastroenterology and hepatology, 11(11), 1517-1520. Elsevier Science |
| ISSN: | 1542-7714 1542-3565 |
| Popis: | Bariatric surgery reduces nonalcoholic fatty liver disease (NAFLD). We investigated the effects of duodenal-jejunal bypass liner (DJBL), nonsurgical bariatric device, on plasma parameters of NAFLD. Seventeen obese subjects with type 2 diabetes received the DJBL for 24 weeks. Before, during, and after DJBL implantation, we determined plasma levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyltransferase (gamma-GT), albumin, caspase-cleaved cytokeratin-18 (CK-18), and liver fatty acid-binding protein (L-FABP). At baseline, subjects had increased levels of AST (35 +/- 4 IU/L), ALT (54 +/- 5 IU/L), and gamma-GT (66 +/- 14 IU/L), compared with healthy individuals; subjects' mean concentrations of caspase-cleaved CK-18 and L-FABP were 214.4 +/- 35.6 U/L and 29.3 +/- 2.6 ng/mL, respectively. Three months after implantation of DJBL, all NAFLD-related parameters had decreased from baseline (AST, 28 +/- 3 IU/L; ALT, 32 +/- 2 IU/L; gamma-GT, 44 +/-7 IU/L; caspase-cleaved CK-18, 140.6 +/- 16.3U/L; and L-FABP, 18.2 +/- 1.5 ng/mL; all P < .05). After 6 months, levels of ALT and gamma-GT had further decreased (ALT, 28 +/- 2 IU/L and gamma-GT, 35 +/- 5 IU/L), whereas levels of AST, caspase-cleaved CK-18, and L-FABP had stabilized (P = not significant). Six months after DJBLs were removed, levels of ALT (37 +/- 3 IU/L), gamma-GT (42 +/- 5 IU/L), and caspase-cleaved CK-18 (124.5 +/- 12.5U/L) were still reduced (P < .05), whereas AST and L-FABP had returned to near baseline levels (P = not significant). Therefore, in obese subjects, DJBL reduces plasma parameters of NAFLD. ClinicalTrials.gov, Number: NCT00985114. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|